Table 1 Baseline characteristics of the entire cohort
Variables | SNUH (n = 421) | EUMC (n = 176) | SMC (n = 739) | P |
|---|---|---|---|---|
Sex | ||||
Male | 333 (79.1) | 141 (80.1) | 583 (78.9) | 0.938 |
Female | 88 (20.9) | 35 (19.9) | 156 (21.1) | |
Age (year) | 63 (54–71) | 69 (59–78) | 63 (56–70) | < 0.001 |
Etiology | ||||
HBV | 265 (63.0) | 121 (74.6) | 517 (70.0) | 0.005 |
HCV | 56 (13.3) | 26 (16.0) | 97 (13.1) | |
alcohol | 45 (10.7) | 15 (9.4) | 67 (9.0) | |
Cirrhosis | ||||
Yes | 336 (79.8%) | 134 (76.1%) | 443 (60.0) | < 0.001 |
Child-Pugh classa | ||||
A | 336 (79.8) | 143 (81.3) | 638 (86.3) | 0.010 |
B | 85 (20.2) | 33 (18.8) | 101 (13.7) | |
BCLC stage | ||||
A | 168 (39.9) | 69 (39.2) | 500 (67.7) | < 0.001 |
B | 253 (60.1) | 107 (60.8) | 239 (32.3) | |
ALBI grade | ||||
1 | 159 (37.8) | 45 (25.6) | 339 (45.9) | < 0.001 |
2 | 245 (58.2) | 118 (67.0) | 385 (52.1) | |
3 | 17 (4.0) | 13 (7.4) | 15 (2.0) | |
HAP score | ||||
A | 157 (37.3) | 58 (33.0) | 233 (31.5) | 0.016 |
B | 134 (31.8) | 47 (26.7) | 252 (34.1) | |
C | 106 (25.2) | 48 (27.3) | 204 (27.6) | |
D | 24 (5.7) | 23 (13.1) | 50 (6.8) | |
Modified HAP score | ||||
A | 211 (50.1) | 71 (40.4) | 98 (13.3) | < 0.001 |
B | 150 (35.6) | 67 (38.1) | 259 (35.0) | |
C | 55 (13.1) | 29 (16.5) | 235 (31.8) | |
D | 5 (1.2) | 9 (5.1) | 147 (19.9) | |
Tumor number | ||||
≤3 | 349 (82.9) | 143 (81.7) | 619 (82.8) | 0.715 |
> 3 | 72 (17.1) | 32 (18.2) | 120 (16.2) | |
Tumor size (cm) | ||||
< 3 | 179 (42.5) | 68 (38.6) | 304 (41.1) | < 0.001 |
3–5 | 129 (30.6) | 51 (29.0) | 163 (22.1) | |
≥5 | 113 (26.8) | 57 (32.4) | 272 (36.8) | |
Hemoglobin (g/dL) | 13.0 (11.8–14.3) | 13.2 (11.3–14.5) | 13.8 (12.7–14.8) | < 0.001 |
WBC (×103/μL) | 5.1 (3.9–6.3) | 5.1 (3.9–6.3) | 5.1 (4.0–6.6) | 0.430 |
Platelet (× 103/μL) | 120 (81–165) | 132 (91–179) | 129 (87–175) | 0.406 |
Prothrombin time (INR) | 1.1 (1.0–1.2) | 1.1 (1.1–1.2) | 1.1 (1.1–1.2) | < 0.001 |
Creatinine (mg/dL) | 0.8 (0.7–1.0) | 0.9 (0.8–1.1) | 0.9 (0.8–1.0) | < 0.001 |
Sodium (mEq/L) | 141 (139–142) | 139 (137–141) | 140 (138–142) | < 0.001 |
AST (mg/dL) | 42 (29–64) | 44 (33–63.5) | 49 (34–72) | 0.089 |
ALT (mg/dL) | 34 (22–54) | 33 (23–53.5) | 38 (24–58) | 0.322 |
Total bilirubin (mg/dL) | 0.8 (0.6–1.2) | 0.8 (0.6–1.1) | 0.8 (0.6–1.1) | 0.487 |
Albumin (g/dl) | 3.8 (3.4–4.1) | 3.7 (3.4–4.0) | 3.9 (3.5–4.2) | 0.233 |
Alpha-fetoprotein (ng/mL) | ||||
≥200 | 89 (21.1) | 49 (28.5) | 194 (26.3) | 0.084 |
< 200 | 332 (78.9) | 123 (71.5) | 545 (73.4) | |
NLR | 1.85 (1.3–2.6) | 1.90 (1.3–3.1) | 1.6 (1.2–2.2) | < 0.001 |
No. of TACE sessions | 2 (1–2) | 2 (1–4) | 4 (2–7) | < 0.001 |
Tumor response | ||||
CR + PR | 332 (78.9%) | 57 (32.4%) | 616 (83.4) | < 0.001 |
SD + PD | 89 (21.1%) | 119 (67.6%) | 123 (16.6) | |